Status:
UNKNOWN
Toripalimab Combined With Anlotinib for Patients With Advanced, Relapsed, or Refractory Gastric, or Esophagogastric Junction Cancer (EGJC)
Lead Sponsor:
The Affiliated Hospital of Qingdao University
Conditions:
Gastric or Gastro-oesophageal Junction Carcinoma
Advanced, Relapsed Gastric or Gastro-oesophageal Junction Carcinoma
Eligibility:
All Genders
18-90 years
Brief Summary
Patients were aged \>18 years with histological confirmed GC/EGJC and were refractory to the first line of therapy. Additional eligibility requirements included: ≥1 measurable disease at baseline per ...
Eligibility Criteria
Inclusion
- Patients were aged \>18 years with histological confirmed GC/EGJC and were refractory to the first line of therapy. Additional eligibility requirements included: ≥1 measurable disease at baseline per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v 1.1); Eastern Cooperative Oncology Group Performance status of 0 or 1; or life expectancy of ≥ 3 months and adequate organ function.
Exclusion
- The main exclusion criteria were interstitial lung disease, pulmonary fibrosis, active or prior autoimmune disease or active hepatitis, or history of anlotinib or any other PD-L1/PD-1 antagonist treatment. Patients with abdominal fistula, diverticulitis, gastrointestinal ulcerative disease or perforation, or abdominal abscess within the prior 4 weeks were also excluded.
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2023
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT04713059
Start Date
January 1 2020
End Date
January 1 2023
Last Update
July 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xiaochun Zhang
Qingdao, China, 266003